Dr. Mims Discusses Momelotinib in Myelofibrosis

Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

The SIMPLIFY-1 study investigated momelotinib to determine if it was non-inferior to ruxolitinib (Jakafi). It did show non-inferiority of splenic size for patients with myelofibrosis, states Mims.

The SIMPLIFY-2 attempted to determine if momelotinib was superior to ruxilitinib. It was not superior but there was improvement in anemia. There will be some role for momelotinib in the future for these patients, states Mims.